ResMed Research and Development Expenses 2010-2024 | RMD

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

ResMed annual research and development expenses for 2024 were $0.308B, a 6.91% increase from 2023.
ResMed annual research and development expenses for 2023 were $0.288B, a 13.43% increase from 2022.
ResMed annual research and development expenses for 2022 were $0.254B, a 12.56% increase from 2021.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

ResMed annual research and development expenses for 2024 were $0.308B, a 6.91% increase from 2023.
ResMed annual research and development expenses for 2023 were $0.288B, a 13.43% increase from 2022.
ResMed annual research and development expenses for 2022 were $0.254B, a 12.56% increase from 2021.

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$231B
Boston Scientific (BSX)	$155.5B
Stryker (SYK)	$147.4B
EssilorLuxottica (ESLOY)	$140.8B
Medtronic (MDT)	$112.8B
Lonza Group Ag (LZAGY)	$47.1B
Haleon (HLN)	$44.8B
GE HealthCare Technologies (GEHC)	$42.1B
Agilent Technologies (A)	$39B
Terumo (TRUMY)	$26.3B
Koninklijke Philips (PHG)	$23.5B
Zimmer Biomet Holdings (ZBH)	$20.6B
Insulet (PODD)	$20.2B
Baxter (BAX)	$17.1B
Sunny Optical Technology (SNPTF)	$11.3B
Smith & Nephew SNATS (SNN)	$11.2B
BellRing Brands (BRBR)	$9.5B
Bio-Rad Laboratories (BIO)	$8B
Demant (WILYY)	$7.9B
Lantheus Holdings (LNTH)	$5.6B
Prestige Consumer Healthcare (PBH)	$4.2B
ICU Medical (ICUI)	$4B
Envista Holdings (NVST)	$3.7B
Perrigo (PRGO)	$3.4B
Haemonetics (HAE)	$3.2B
Shandong Weigao Medical Polymer (SHWGF)	$3B
GN Store Nord (GNNDY)	$2.9B
QuidelOrtho (QDEL)	$2.8B
LeMaitre Vascular (LMAT)	$2.3B
Neogen (NEOG)	$2.2B